Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Manuel L. Penichet, M.D., Ph.D.
Manuel L. Penichet, M.D., Ph.D.

Affiliation(s):

Associate Professor, Department of Surgery
Member, JCCC Tumor Immunology Program Area

Contact Information:

Phone:
(310) 825-1304
Email:

Scientific Interest(s):

Since 1996, Dr. Manuel Penichet has worked at UCLA, where he has developed a family of antibody fusion proteins to be used as direct anti-tumor agents and as adjuvant of cancer vaccines. Recently he has developed antibody-avidin fusion proteins to be used as universal vectors to deliver a broad spectrum of biotinylated compounds into cancer cells by receptor-mediated endocytosis.

Selected Cancer-Related Publications:

Daniels TR, Leuchter RK, Quintero R, Helguera G, Rodríguez JA, Martínez-Maza O, Schultes BC, Nicodemus CF, Penichet ML. Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother. 2012 Jul;61(7):991-1003. Epub 2011 Nov 30

Daniels TR, Ortiz-Sánchez E, Luria-Pérez R, Quintero R, Helguera G, Bonavida B, Martínez-Maza O, Penichet ML. An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies. J Immunother. 2011 Jul-Aug;34(6):500-8.

Helguera G, Rodríguez JA, Luria-Pérez R, Henery S, Catterton P, Bregni C, George TC, Martínez-Maza O, Penichet ML. Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry. J Immunol Methods. 2011 May 31;368(1-2):54-63. Epub 2011 Mar 21

Daniels TR, Neacato II, Rodríguez JA, Pandha HS, Morgan R, Penichet ML. Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. Leukemia. 2010 Sep;24(9):1555-65. Epub 2010 Jun 24

Ortiz-Sánchez E, Daniels TR, Helguera G, Martinez-Maza O, Bonavida B, Penichet ML. Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia. 2009 Jan;23(1):59-70. Epub 2008 Oct 23

Dela Cruz JS, Morrison SL, Penichet ML. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. Vaccine. 2005; 23(39): 4793-803.

Dela Cruz JS, Huang TH, Penichet ML, Morrison SL. Antibody-cytokine fusion proteins: innovative weapons in the war against cancer. Clin Exp Med. 2004; 4(2): 57-64.